​

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

SEHK:2315 Stock Report

Market Cap: HK$8.4b

Biocytogen Pharmaceuticals (Beijing) (2315) Stock Overview

A biotechnology company, engages in the research and development of novel antibody-based drugs in the People’s Republic of China, the United States, and internationally. More details

2315 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health3/6
Dividends0/6

Rewards

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months compared to the Hong Kong market


2315 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biocytogen Pharmaceuticals (Beijing)
Historical stock prices
Current Share PriceHK$20.30
52 Week HighHK$24.15
52 Week LowHK$5.60
Beta0.23
1 Month Change-8.76%
3 Month Change69.45%
1 Year Change178.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-21.92%

Recent News & Updates

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Shares Fly 27% But Investors Aren't Buying For Growth

May 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Shares Fly 27% But Investors Aren't Buying For Growth

We Think Biocytogen Pharmaceuticals (Beijing)'s (HKG:2315) Robust Earnings Are Conservative

May 01
We Think Biocytogen Pharmaceuticals (Beijing)'s (HKG:2315) Robust Earnings Are Conservative

Recent updates

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Shares Fly 27% But Investors Aren't Buying For Growth

May 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Shares Fly 27% But Investors Aren't Buying For Growth

We Think Biocytogen Pharmaceuticals (Beijing)'s (HKG:2315) Robust Earnings Are Conservative

May 01
We Think Biocytogen Pharmaceuticals (Beijing)'s (HKG:2315) Robust Earnings Are Conservative

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking After Shares Rocket 91%

Mar 27
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking After Shares Rocket 91%

Health Check: How Prudently Does Biocytogen Pharmaceuticals (Beijing) (HKG:2315) Use Debt?

Dec 12
Health Check: How Prudently Does Biocytogen Pharmaceuticals (Beijing) (HKG:2315) Use Debt?

Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?

May 08
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking

Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking

Shareholder Returns

2315HK BiotechsHK Market
7D-4.5%-3.1%1.0%
1Y178.8%120.3%27.8%

Return vs Industry: 2315 exceeded the Hong Kong Biotechs industry which returned 120.3% over the past year.

Return vs Market: 2315 exceeded the Hong Kong Market which returned 27.8% over the past year.

Price Volatility

Is 2315's price volatile compared to industry and market?
2315 volatility
2315 Average Weekly Movement12.2%
Biotechs Industry Average Movement10.3%
Market Average Movement6.8%
10% most volatile stocks in HK Market15.5%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 2315's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2315's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
20081,117Yuelei Shenbiocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4-tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary

How do Biocytogen Pharmaceuticals (Beijing)'s earnings and revenue compare to its market cap?
2315 fundamental statistics
Market capHK$8.45b
Earnings (TTM)HK$36.72m
Revenue (TTM)HK$1.07b
220.8x
P/E Ratio
7.6x
P/S Ratio

Is 2315 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2315 income statement (TTM)
RevenueCN¥980.45m
Cost of RevenueCN¥204.74m
Gross ProfitCN¥775.71m
Other ExpensesCN¥742.17m
EarningsCN¥33.54m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.084
Gross Margin79.12%
Net Profit Margin3.42%
Debt/Equity Ratio47.9%

How did 2315 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/14 16:29
End of Day Share Price 2025/07/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCMB International Securities Limited
Ziyi ChenGoldman Sachs
Kehan MengHaitong International Research Limited